Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract April 2014

Patient Adherence and Persistence with Topical Bimatoprost ® 0.01% and Bimatoprost ® 0.03%: an Analysis of Latanoprost Switchers

Jonathan W Kowalski; Joanna Campbell; Gail F Schwartz; Britni LaBounty

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):540.

ARVO Annual Meeting Abstract April 2011

Evaluating Adherence of Fixed Dose Brimonidine/Timolol Compared With Fixed Dose Dorzolamide/Timolol or Multiple Bottle Combinations

Gail F. Schwartz; Vaishali Patel; Caroline Burk; Paul Buzinec; Robert J. Morlock

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5546.

ARVO Annual Meeting Abstract April 2010

Patient Persistency With Topical Glaucoma Therapy is Higher With Fixed Dose Brimonidine/Timolol Than With Two-Bottle Combinations

G. F. Schwartz; V. D. Patel; C. Burk; T. Bennett

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):185.

ARVO Annual Meeting Abstract April 2010

Incidence of Dry Eye or Ocular Infection in Open-Angle Glaucoma (OAG) and Ocular Hypertension (OH) Patients Treated With Latanoprost (LAT) With BAK or Travoprost-Z (TRAV-Z) With SofZiaTM

S. Kotak; G. F. Schwartz; J. Mardekian; J. Fain

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):2762.

ARVO Annual Meeting Abstract April 2009

Hyperemia-associated Costs of Medication Changes in Glaucoma Patients Treated Initially with Prostaglandin Analogs

S. Kotak; G. F. Schwartz; J. Tan

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4088.

ARVO Annual Meeting Abstract April 2009

1-Year Incidence of Dry Eye in Open-Angle Glaucoma (OAG) and Ocular Hypertension (OH) Patients Treated With Latanoprost (LAT) or Travoprost-Z (TRAV-Z)

G. F. Schwartz; J. Fain; J. Mardekian; S. Kotak

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4653.

ARVO Annual Meeting Abstract May 2008

Persistence on Prostaglandin Ocular Hypotensive Therapy: An Assessment Using Medication Possession and Days of Coverage on Therapy

S. Kotak; G. F. Schwartz; G. Reardon; S. N. Shah

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):3212.

ARVO Annual Meeting Abstract May 2008

Evaluating Adherence and Readiness for Behavior Change in Patients Prescribed Ocular Hypotensive Therapy

G. F. Schwartz; K. Plake; M. A. Mychaskiw

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):4983.

ARVO Annual Meeting Abstract May 2008

Using Area Under the Survival Curve to Estimate Cost-Effectiveness of Topical Ocular Hypotensives for Maintaining Persistent Therapy

G. Reardon; G. F. Schwartz; S. Kotak

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):4988.

ARVO Annual Meeting Abstract May 2007

Assessing Behavior and Readiness for Behavior Change in Patients Taking Ocular Hypotensive Therapy

G. F. Schwartz; K. Plake; M. A. Mychaskiw

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):2401.

Advertisement